Nivolumab Plus Chemotherapy Improves Survival Outcomes in Gastric and Esophageal Cancers

Nivolumab (Opdivo) in combination with chemotherapy as a frontline treatment demonstrated a significant survival benefit in patients with metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, or esophageal adenocarcinoma, according to findings from the phase 3 CheckMate-649 trial (NCT02872116).1

https://www.oncnursingnews.com/web-exclusives/nivolumab-plus-chemotherapy-improves-survival-outcomes-in-gastric-and-esophageal-cancers